Healthcare Holding B.V. Gilde Sells 2,095 Shares of Shoulder Innovations (NYSE:SI) Stock

Shoulder Innovations, Inc. (NYSE:SI) major shareholder Healthcare Holding B.V. Gilde sold 2,095 shares of Shoulder Innovations stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $22.60, for a total transaction of $47,347.00. Following the completion of the transaction, the insider owned 2,212,207 shares of the company’s stock, valued at $49,995,878.20. This trade represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Wednesday, August 5th, Healthcare Holding B.V. Gilde sold 7,338 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.64, for a total value of $166,132.32.
• On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.77, for a total value of $2,272,719.24.
• On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.71, for a total value of $244,155.21.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.73, for a total value of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The stock was sold at an average price of $23.36, for a total value of $659,803.20.

Shoulder Innovations Stock Performance

Shares of NYSE:SI opened at $20.54 on Friday. Shoulder Innovations, Inc. has a twelve month low of $10.92 and a twelve month high of $24.59. The firm has a market cap of $426.06 million and a PE ratio of -10.70. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.04 and a current ratio of 11.81. The business has a fifty day moving average of $19.91 and a 200-day moving average of $16.07.

Shoulder Innovations (NYSE:SI) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.03. Shoulder Innovations had a negative net margin of 58.33% and a negative return on equity of 22.93%. The business had revenue of $16.71 million for the quarter. On average, equities research analysts predict that Shoulder Innovations, Inc. will post -1.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Shoulder Innovations

Several institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Shoulder Innovations during the third quarter worth approximately $28,000. Rhumbline Advisers acquired a new stake in Shoulder Innovations during the 3rd quarter worth $54,000. Wells Fargo & Company MN raised its position in shares of Shoulder Innovations by 66.3% during the 4th quarter. Wells Fargo & Company MN now owns 5,250 shares of the company’s stock valued at $75,000 after acquiring an additional 2,094 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Shoulder Innovations during the 4th quarter valued at $176,000. Finally, Blue Trust Inc. acquired a new position in shares of Shoulder Innovations in the 1st quarter valued at $228,000.

Shoulder Innovations News Roundup

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
• Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
• Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
• Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
• Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
• Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SI. Weiss Ratings raised shares of Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, August 3rd. BTIG Research increased their price objective on Shoulder Innovations from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Friday. Piper Sandler reissued an “overweight” rating and issued a $25.00 target price (up from $19.00) on shares of Shoulder Innovations in a research note on Friday. Finally, UBS Group began coverage on Shoulder Innovations in a research report on Tuesday, July 28th. They set a “buy” rating and a $27.00 target price for the company. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Shoulder Innovations currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.33.

Shoulder Innovations Company Profile

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.